G-xpect Pse
NDC 43913-407
Product Information
G-xpect Pse is a OTC MONOGRAPH FINAL-approved product labeled by Mclaren Medical. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a product. This product entry covers the primary NDC 43913-407 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
Code Structure Chart
Product Details
What is NDC 43913-407?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- DEXTROMETHORPHAN HYDROBROMIDE (UNII: 9D2RTI9KYH)
- DEXTROMETHORPHAN (UNII: 7355X3ROTS) (Active Moiety)
- GUAIFENESIN (UNII: 495W7451VQ)
- GUAIFENESIN (UNII: 495W7451VQ) (Active Moiety)
- PSEUDOEPHEDRINE HYDROCHLORIDE (UNII: 6V9V2RYJ8N)
- PSEUDOEPHEDRINE (UNII: 7CUC9DDI9F) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SODIUM BENZOATE (UNII: OJ245FE5EU)
- CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)
- SORBITOL (UNII: 506T60A25R)
- SACCHARIN SODIUM (UNII: SB8ZUX40TY)
- SUCRALOSE (UNII: 96K6UQ3ZD4)
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1421983 - dextromethorphan HBr 10 MG / guaiFENesin 200 MG / pseudoephedrine HCl 30 MG in 5 mL Oral Solution
- RxCUI: 1421983 - dextromethorphan hydrobromide 2 MG/ML / guaifenesin 40 MG/ML / pseudoephedrine hydrochloride 6 MG/ML Oral Solution
- RxCUI: 1421983 - dextromethorphan hydrobromide 10 MG / guaifenesin 200 MG / pseudoephedrine hydrochloride 30 MG per 5 ML Oral Solution
* Please review the full disclaimer at the bottom of this page.